Navigation Links
Researchers use DNA to build tool that may literally shine light on cancer
Date:5/7/2014

Bioengineers at the University of Rome Tor Vergata and the University of Montreal have used DNA to develop a tool that detects and reacts to chemical changes caused by cancer cells and that may one day be used to deliver drugs to tumor cells.

The researchers' nanosensor measures pH variations at the nanoscale how acidic (a higher pH level) or alkaline (a lower pH level) it is. Many biomolecules, such as enzymes and proteins, are strongly regulated by small pH changes. These changes affect in turn biological activities such as enzyme catalysis, protein assembly, membrane function and cell death. There is also a strong relation between cancer and pH.

Cancer cells often display a lower pH compared to normal cells: the pH level inside cancer cells is higher than it is outside. "In living organisms, these small pH changes typically occur in tiny areas measuring only few hundred nanometers," says senior author Prof. Francesco Ricci. "Developing sensors or nanomachines that can measure pH changes at this scale should prove of utility for several applications in the fields of in-vivo imaging, clinical diagnostics and drug-delivery."

"DNA represents an ideal material to build sensors or nanomachines at the nanometer scale" says senior author Prof. Valle-Blisle. "By taking advantage of a specific DNA sequences that form pH-sensitive triple helix, we have designed a versatile nanosensor that can be programmed to fluoresce only at specific pH values." Fluorescence is the emission of radiation, including visible light, caused by an exchange of energy. "This programming ability represents a key feature for clinical applications we can design a specific sensor to send a fluorescent signal only when the pH reaches a specific value which is, for example, characteristic of a specific disease," adds first author Andrea Idili.

In the future, this recently patented nanotechnology may also find applications in the development of novel drug-delivery platforms that release chemio-therapeutic drugs only in the viscinity of tumor cells.


'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-566-3813
University of Montreal
Source:Eurekalert  

Related medicine news :

1. Sleep researchers at SRI International identify promising new treatment for narcolepsy
2. Chimpanzees show similar personality traits to humans, Georgia State researchers say
3. Researchers present findings on promising biomarker for esophageal cancer
4. Bioinformatics approach helps researchers find new uses for old drug
5. BrightFocus honors 5 vision researchers
6. Researchers link age, general health and antidepressant use with eye disorders
7. Researchers granted funding to explore novel lung cancer strategies
8. MS researchers find brain & cognitive reserve protect long-term against cognitive decline
9. UNC researchers discover master regulator role for little-known protein in cancer cells
10. CWRU researchers profile womens employment, caregiving workloads, effort and health
11. Drug monitoring information improves regimen adherence, Carnegie Mellon researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers use DNA to build tool that may literally shine light on cancer
(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier ... professionals caring for those suffering from the full spectrum of disordered eating, announced today ... disorders professionals from nearly all 50 states and several countries converged on the Green ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the ... product – with nearly 2,000 consumers (and counting) already backing the campaign. ...
(Date:3/24/2017)... Oakland, CA (PRWEB) , ... March 24, 2017 ... ... present on two panels at the Advanced ERISA Benefit Claims Litigation seminar in ... and Creating the Administrative Record, The majority of cases litigated under ERISA involve ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ... prep patients for colonoscopy at the HyGIeaCare® Center that is to be located ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... to Walk with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward ... Learning How to Walk with God #TruthwithGrace” is the creation of published author ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... 2016" report to their offering. ... The IPF pipeline is very strong with a total of ... Co., Inc., Biogen and Sanofi are involved in the development of the ... one is in Phase III stage, 15 are in Phase II stage, ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
Breaking Medicine Technology: